Background/Aims: Based on the protective effect of crocin against cardiovascular diseases, we hypothesize that crocin could improve endothelial function through activating the eNOS(endothelial nitric oxide synthase) /NO pathway and/or the intermediate-conductance Ca 2+ -activated K + channels (KCa3.1). Methods: In this study, rat aortic rings were used to assess the regulatory effect of crocin on vascular tone and nitric oxide, prostacyclin, and KCa3.1, all endothelial vasodilators, were analyzed for effects by crocin. The expression profiles of p-eNOS, total-eNOS, p-ERK, total-ERK, p-Akt, total-Akt, KCa3.1, CD31, thrombomodulin, ICAM-1 and VCAM-1 were tested by western blotting. KCa3.1 was also analyzed by qPCR and immunofluorescence staining. Fluorescence and confocal microscopy were used to determine NO generation and intracellular Ca 2+ . Both EdU and MTT assays were used to evaluate cell viability. Cellular migration was assessed using transwell assay. Results: Crocin relaxed pre-contracted artery rings through either NO or KCa3
as well as the cell proliferation and migration in vitro. All of these effects were abrogated by three inhibitors: PD98059, MK-2206 and TRAM-34, respectively. Despite these positive effects, crocin could not affect the expression of intercellular cell adhesion molecule-1 (ICAM-1). We report for the first time that the protective character of crocin on endothelium is modulated by KCa3.1, and the underlying mechanism may be attributed to KCa3.1-induced hyperpolarization and -controlled intracellular Ca 2+ .
Materials and Methods

Reagents
Crocin and PD98059 were purchased from Santa Cruz (USA). MK-2206 was purchased from Selleck (USA). TRAM-34 was purchased from Sigma (USA). EdU Cell Proliferation Assay kit and riboFECT CP Transfection kit were purchased from Ribobio (China). DAF-FM DA and Fluo-3-AM kits were purchased from Beyotime Biotechnology (China). The rabbit antibody against KCa3.1 was purchased from Abcam (USA). Rabbit antibodies against p-ERK, total-ERK (t-ERK), TM, ICAM-1, VCAM-1 and mouse antibodies against CD31 were purchased from Proteintech (USA). Rabbit and mouse antibodies against β-actin were all purchased from Santa Cruz (USA).
Cell culture
The HUVECs and HUAECs (ScienCell, USA) were cultivated at 37 °C in a humidified incubator with 5% CO 2 in endothelial cell medium (ECM), which was supplemented with 5% fetal bovine serum (FBS), 1% endothelial cell growth supplement (ECGS) and 1% penicillin/streptomycin solution (PS). Passages 3-10 of HUVECs and HUAECs were used for the following studies.
Animals
In this study, adult male Sprague Dawley (SD), weighting 250-300g, were supplied by the Experimental Animal Center of China Pharmaceutical University. The animal experimental procedure was also approved by the Institutional Animal Care and Use Committee of China Pharmaceutical University.
Myograph study
Aortic rings of SD rats were prepared as previously described [27] . The aorta was rapidly excised and carefully dissected from surrounding connective tissue and cut into 3mm length rings in ice-cold Krebs buffer (composition, mM: NaCl, 118; KCl, 4.75; KH 2 PO 4 , 1.19; MgSO 4 ·7 H 2 O, 1.19; CaCl 2 ·2 H 2 O, 2.5; d-glucose, 11.1; NaHCO 3 , 25) . A portion of the total harvest of aortic rings were further denuded of the endothelium with a metal probe. The remaining aortic rings with no damage were used as endothelium-intact rings. The prepared rings were then mounted on a myograph (Xinhang JZ101, Beijing) to measure tension and were analyzed using BL420F software. All rings were initially equilibrated under 1g passive tension for 60 min in Krebs buffer which was continuously bubbled with 95 % O 2 and 5 % CO 2 at 37 °C before further evaluation. In a portion of this research, aortic rings were pre-contracted with the α-receptor agonist PE (10 -5 ) μmol/L were added to detect vasodilator effects. In order to test the contractive response of PE to aortic rings pre-treated with crocin, rings were treated with crocin (10 -5 mol/L) for 30 min prior to contraction by PE (10 -9 -10 -5 mol/L).
Small interference RNA (siRNA) transfection
Transfection technique was designed to knock down KCa3.1 gene (KCNN4) by siRNA in HUVECs. KCa3.1 siRNA (siKCa3.1) and negative control siRNA (NC) were purchased from RiboBio Co., Ltd., China. Cells were cultured to 50%-75% confluence, 100 nM siRNA were used to transfect the cells with the riboFECT™ CP reagent (RiboBio Co., Ltd., Guangzhou, China) according to manufacturer's protocol. The cells were treated with crocin for 48 h after siRNA transfection. The negative siRNA and transfection agent alone were used as controls.
Quantitative real-time PCR (qPCR)
Total RNA was extracted from transfected cells by TRIZOL reagent (Invitrogen) according to the manufacture's protocol, and reverse transcribed into cDNA with the Reverse Transcriptase kit (Promega, Madison, WI). Real time PCR analyses for KCa3.1 gene (KCNN4) was performed using a LightCycler® 96 System (Roche) in a 20 μl reaction mixture contained 10 μL of SYBR ® Green PCR Master Mix (Applied Biosystems), 4 pmol of forward and reverse primers each, and 1 μL of cDNA. The cycling conditions were as follows: 30 s at 95 °C, then 40 cycles of 95 °C for 5 s, and 60 °C for 30 s. GAPDH was used as an internal control. Primer construction is shown in Table 1 .
Western blotting analysis
Western blotting was performed according to published method [27] . After the indicated pretreatments, the cells were rinsed with ice-cold PBS and lysed in Triton X-100 buffer to extract the protein. Total protein concentration was measured using BCA Protein Assay Reagent (Pierce, Rockford, IL, USA), with bovine serum albumin (BSA) as the standard. Equal amounts of proteins from experimental groups were subjected to SDS-PAGE and transferred to nitrocellulose filter (NC) membrane. The membranes were blocked with 5% nonfat dry milk and probed with the primary antibody. These primary antibodies include KCa3.1, p-ERK, t-ERK, p-eNOS, t-eNOS, COX-1/2, β-actin, CD31, TM, VCAM-1 and ICAM-1. After washing, the membrane was treated with horseradish peroxidase (HRP)-conjugated secondary antibodies, followed by enhanced chemiluminescence (ECL) reagent (Amersham Pharmacia Biotech). The band intensities were quantified using Quantity-One software 4.6.2 (Bio-Rad).
Determination of NO production in endothelial cells
To examine the effect of crocin on NO generation in endothelial cells, we used 4-amino-5-methylamino-2, 7-difluorofluorescein diacetate (DAF-FM DA) (Beyotime, China), a probe for NO, to measure NO levels in cytoplasm as described previously [28] . Cells were seeded onto slides coated by 0.1 mg/ml Poly-L-Lysine in 24-well plates and then incubated with 5 μmol/L DAF-FM DA for 30 min at 37°C, 5%CO 2 . Cells were then cultured in medium with crocin at concentrations of 0, 0.1, 1, 10 and 100 µmol/L in the presence and absence of the inhibitors PD98059 (20 μmol/L a MEK inhibitor), MK-2206 (2 μmol/L an Akt inhibitor) and TRAM-34 (10 μmol/L a KCa3.1 inhibitor) for 1.5 h. The slides were then washed with PBS to remove excess probe. The slides were then evaluated for fluorescence at wavelength 495 nm using an Olympus-BX51 fluorescence microscope (Olympus, Japan). The fluorescence intensity (mean option density, MOD) was analyzed using Image Pro-Plus 6.0 software. MOD = Integrated option density (IOD)/cell numbers.
Ca
2+ measurements The intracellular Ca 2+ was measured in situ by fluorescence and/or confocal microscopy using Fluo-3-AM (Beyotime, China), a probe for Ca 2+ . After crocin treatments with or without the previously mentioned three inhibitors, cells were incubated in serum-free ECM containing 5 Μmol/L Fluo-3 for 30 min at 37 °C. The cells were then washed using Hank's Balanced Salt Solution (HBSS), for the removal of excess dye. Intracellular fluorescence intensity was evaluated as described above for NO production determination.
Cell viability analysis
Cell viability was evaluated using the 5-Ethynyl-2'-deoxyuridine (EdU) proliferation and methylthiazolyldiphenyl-tetrazolium (MTT) proliferation assays. For the EdU assay, cells were seeded on the fibronectin-coated slides in 24-well plates and incubated in serum-free medium without ECGS overnight. Cells were treated with or without crocin, or the inhibitors PD98059, MK-2206 and TRAM-34, for 24 h and 48 h, respectively. Where indicated, cells were pre-treated with the aforementioned inhibitors for 30 min before crocin treatment in all inhibition studies. The cells were then stained for EdU according to the manufacturer's protocol. The cell nuclei were then stained with DAPI (1 g/L) for 10 min, and finally EdUlabeled cells were evaluated by fluorescence microscopy (OLYMPUS, IX71). For the MTT assay, 1×10 4 cells were seeded in 96-well plates, under the same conditions as for the EdU evaluation. The MTT assay was then performed according to the manufacturer's protocol. The absorbance at 490 nm was measured using an absorbance microplate reader (Molecular Devices, M2).
Migration assay
Transwell assay was used to assess the cell migration. Cells were seeded at a concentration of 2×10 4 cells in 250 μL ECM containing 0.2 % FBS in the upper chamber of transwell insert with 8 μm pore size in 24-well plates. Five hundred microliters of ECM containing 5 % FBS with or without crocin and inhibitors were added to the lower chamber. After incubation at 37°C for 36-48 h, cells on the upper side of chamber were removed, followed by methanol fixation and crystal violet staining. Fixated and stained chambers were then photographed for quantification analysis.
Statistics
The data of at least three experiments were presented as the mean ± SD. Statitstical analysis of the data was performed using Student's t-test or one-way analysis of variance (ANOVA). Differences with P values ≤0.05 are considered statistically significant.
Results
Crocin promotes the endothelium-dependent vasorelaxation of rat aortic rings
Crocin was used to test the vasodilator effect of PE or the contractive effect of acetylcholine (ACh), respectively, in endothelium-intact rings in order to assess the regulatory effect of crocin on the vascular tone in aortic rings. Our results showed that crocin could noticeably relax artery rings pre-contracted by PE in a dose-dependent manner, but could not contract the endothelial-dependent relaxed ACh-pretreated rings (data not shown). Interestingly, crocin had no vasodilator effect on the artery rings in the absence of PE in this present work. Furthermore, crocin significantly attenuated the contractive effect of PE in endotheliumintact rings, not in endothelium-denuded rings (Fig. 1A) , with an EC50 of 0.3585 μmol/L for relaxation (Fig. 1B) . This data illustrated that crocin relaxed the pre-contracted artery rings in an endothelium-dependent manner. We then confirmed, as shown in Fig. 1C , that both L-NAME and TRAM-34 noticeably inhibit crocin-induced relaxation, whereas no significant changes were observed in the indomethacin treated group. This indicates that indomethacin had no inhibitory effect on crocin-induced relaxation. These data reveal that crocin may exert its vasodilator effect in pre-contracted artery rings via promotion of NO production or activation of KCa3.1, and not the PGI product. After we pretreated the artery rings with crocin for 30 min, the contractive responses of the artery rings to PE appeared to be insensitive in the crocin-pretreated group as compared to the untreated group. We also noted that crocin significantly weakened the contractive effects of PE in endothelium-intact rings (Fig. 1D ).
Effect of crocin on the expression of eNOS, COX-1/2 and KCa3.1 in endothelial cells
We evaluated the eNOS pathway and the KCa3.1 system by western blotting in order to determine the mechanism of crocin-promoted vasorelaxation. We examined the protein expression of p-NOS at Ser1177, t-eNOS, COX-1, COX-2, and KCa3.1 in HUVECs and HUAECs, respectively. As shown in Fig. 2A -C, crocin could upregulate both the phosphorylated and total expression of eNOS in HUVECs. This resulted in a high ratio of phosphorylated to total eNOS expression. Crocin also increased the expression of COX-2, but not COX-1 ( Fig. 2A, D , E). These results demonstrate that the vasodilator effect of crocin was associated with the upregulation of p-eNOS and t-eNOS, resulting in the enhanced ratio of p-eNOS to t-eNOS. Interestingly, western blot analysis ( Fig. 2F ) and immunofluorescence staining (data not shown) showed that crocin could not alter the expression of KCa3.1 at the protein level in our study. It could be possible that crocin activates KCa3.1 as an agonist-like substance, not causing an increase of KCa3.1 at either the protein or mRNA level, to regulate the vasodilator effect as shown in our myograph study.
ERK and Akt kinases were involved in the crocin stimulated-expression of p-eNOS, t-eNOS and KCa3.1
To examine the possible roles of ERK and Akt in the crocin induction of p-eNOS, t-eNOS and KCa3.1, cells were treated with crocin in the presence and absence of the inhibitors PD98059 and MK-2206, respectively. As demonstrated in Fig. 2G -I, the expression of p-ERK, t-ERK, p-Akt and t-Akt in HUVECs were significantly higher in all crocin-treated groups as compared to the untreated group after 48 h treatment. We observed that crocin could induce the phosphorylation of ERK and Akt kinase, resulting in an increased ratio of phosphorylated to unphosphorylated of ERK and Akt (data not shown). As shown in Fig. 3A , the inhibitors PD98059 and MK-2206 reduced the crocin-upregulated expression of p-eNOS and t-eNOS. This inhibitor effect significantly lowered the proportion of eNOS phosphorylated at Fig. 3C and D, KCa3.1 mRNA and protein expression in the siKCa3.1 group was significantly inhibited as compared with the NC group in HUVECs. The p-eNOS and t-eNOS expression in HUVECs showed no significant difference between siKCa3.1 group and NC group in the absence of crocin. However, in the presence of crocin this difference was markedly decreased in the siKCa3.1 group as compared to NC group (Fig. 3E) . We observed similar results in the TRAM-34 plus crocin group, where TRAM-34 inhibited the p-eNOS and t-eNOS expression in HUVECs (Fig. 3A) . These data illustrate that the expression of p-eNOS and t-eNOS induced by crocin were significantly mediated by KCa3.1.
Crocin stimulates NO production by activating ERK and Akt signaling pathways, as well as the KCa3.1 system in endothelial cells
In this present work, the detection of eNOS-mediated NO production was essential to further evaluate the underlying mechanism with which crocin relaxed pre-contracted artery rings. As shown in Fig. 4A , crocin at concentrations higher than 1 μmol/L significantly promoted NO production in HUVECs compared to the control and 0.1μmol/L group, respectively. This indicates that the elevated NO production in response to crocin was mainly due to the upregulation p-eNOS or t-eNOS expression by crocin. To determine whether ERK, Akt, or KCa3.1 mediated the crocin-induced NO production in endothelium, the aforementioned inhibitors PD98059, MK-2206 and TRAM-34 were used. Fluoresence intensity was significantly decreased in all of three inhibitor groups as compared with the crocin alone (Fig. 4B) . These data illustrate that crocin significantly promotes eNOS-mediated 
NO production in endothelium by activating ERK and Akt signaling pathways, as well as the KCa3.1 system. Similar findings were confirmed in HUAECs (data not shown). μmol/L in HUVECs (Fig. 4C ). This observed increase in intracellular Ca 2+ effect of crocin was reduced with the addition by inhibitors in HUVECs (Fig.4D) . These findings reveal that crocin could regulate the mobilization of intracellular Ca 2+ level via ERK and Akt signaling pathways, as well as the KCa3.1 system.
Crocin increases intracellular Ca
Crocin promotes the expression of CD31, TM, ICAM-1 and VCAM-1 via the ERK and Akt signaling pathways, as well as the KCa3.1 system
Western blotting was used to evaluate the effects of crocin on CD31, TM, ICAM-1, and VCAM-1 expression in HUVECs and HUAECs, respectively. These proteins of interest are associated with the endothelial function in normal and disease states. Results show that the expression of CD31, TM and VCAM-1, but not ICAM-1, increased in the crocin-treated cells as compared to untreated (Fig. 5A-E) . To test whether the ERK and Akt signaling pathways and/or the KCa3.1 system mediate these events, the inhibitors PD98059, MK-2206 and TRAM-34 were added to crocin treated cells. As seen in Fig. 5F -I, the upregulation of CD31, TM and VCAM-1 by crocin is remarkably suppressed by the three inhibitors, respectively. These data suggest that crocin could upregulate the expression of CD31, TM and VCAM-1, but not ICAM-1, through the ERK and Akt signaling pathways. The KCa3.1 system may also function as a mediator of the beneficial effects of crocin on endothelium.
Crocin stimulates cell viability
The cellular proliferation of HUVECs and HUAECs exposed to varying concentrations 0, 0.1, 1, 10 and 100 μmol/L of crocin were analyzed at 24, 48, and 72 h using both EdU and MTT assays (data not shown). As shown in Fig. 6A , crocin induced the proliferation of HUVECs in vitro and demonstrated a significant effect at concentrations higher than 1 μmol/L after 48 h and higher than 10 μmol/L after 72 h, respectively. However, after 24 h these results were not significant. Intriguingly, cell proliferation stimulated by crocin tended to decrease at a concentration of 100 μmol/L at both 48 h and 72 h. We observed similar results in HUAECs (data not shown). These results indicate that cellular viability in crocin exposed cells was time dependent to some extent, not concentration dependent, having peaked at 10 μmol/L. Consequently, crocin concentration at 10 μmol/L was used in the other experiments. Next, we investigated the viability of crocin-stimulated HUVECs treated with the previously mentioned inhibitors. As seen in Fig. 6 B and C, the proliferation percentages of HUVECs in the three inhibitor groups were significantly lower than those in the crocin alone group. Cell proliferation induced by crocin was significantly suppressed by inhibitors PD98059, MK-2206 and TRAM-34, respectively.
Crocin induces cell migration
A transwell assay was performed to examine the migration effects of crocin on HUVECs and HUAECs. As shown in Fig. 7A , the number of migrating cells increased with varying concentrations of crocin, except at 100 μmol/L, as compared with the untreated group. This shows that crocin could significantly induce the migration of HUVECs, however the migration effect of crocin was not concentration dependent. To investigate whether the ERK and Akt signaling pathways were involved in the crocin-induced migration of endothelial cells, and the potential role of KCa3.1 in this process, inhibitors were included in the transwell experiments. Fig. 7 B and C revealed that the numbers of migrating cells remarkably decreased in PD98059 and MK-2206 inhibitors groups, suggesting that PD98059 and MK-2206, but not TRAM-34, could reduce the migration effects of crocin on HUVECs.
Discussion
Endothelium plays a prominent role in the cardiovascular system. Its physiological function where it tightly regulates vascular tone via establishing the balance between vasodilators and vasoconstrictors derived from endothelial cells [1, 14, 15, 29] . The endothelium-derived hyperpolarizing factor (EDHF) is considered to be as equally important as NO and PGI(2) in regulating vascular tone as well as endothelial function in both healthy and diseased states [14, 15, 25] . This factor, which is associated with the hyperpolarization of both endothelial and vascular smooth muscle cells, controls a endothelium-derived hyperpolarization (EDH) process mainly mediated by KCa3.1 [18, 25] . Endothelial dysfunction has long been recognized as an initiating event in the development of numerous cardiovascular diseases [14, 30] . This recognition is due to its influence on the consequential reduction in the synthesis and/or release of eNOS-mediated NO [29, 31] , as well as damage to the EDHF dilator pathway [17, 25] . In short, improvement of endothelial dysfunction may be a novel treatment option for cardiovascular diseases in the future.
Crocin is one of the major pharmacologically bioactive constituents in saffron [1, 5, 32] , and possesses protective effects against cardiovascular diseases [1, 3, [5] [6] [7] 33] . Moreover, the cardiovascular protective effects of crocin are considered to be closely associated with its antioxidant activity [1, 5, 11, 32, 33] . Additional research has also shown that biocompounds from saffron, including crocin, exert a hypotensive effect in normotensive and hypertensive states [1, 7] . However, Llorens, et al. reported that crocetin and crocin, two compounds from saffron, differentially affect vascular contractility in hypertension [1] . They attributed the vasodilator effect to crocetin in endothelium-intact rings and a contractile effect to crocin, respectively [1, 7] . Hypotensive effects and anti-contractile ability have been reported for saffron and its constituents, however the mechanism of crocin action on endothelial modulation of vascular contraction is poorly understood. Our results showed that crocin can significantly relax the aortic ring with intact endothelium, with an ED50 of 0.3585 μmol/L. Curiously, it was our initial finding that the vasodilator effect of crocin was only exhibited in the PE-contracted aortic rings with passive tension, not in the uncontracted artery rings. This suggests that crocin can effectively exert the vasodilator response in a hypertensive state. This enhanced sensitivity of the artery ring to crocin may be due to PE-induced vasoconstriction alluding to a possible mechanism. We further elucidated that crocin could not relax the artery rings when endothelium was absent, which contradicts previous research reporting contraction occurs with crocin treatment on smooth muscle cells [1, 7] . In our present study, we provide strong evidence that crocin relaxed the precontracted artery rings in an endothelium-dependent manner.
Both NO and PGI are the major endothelial vasodilators in artery tissues. In our work, we determined that the eNOS-mediated NO pathway, at least partially, was involved in the vasodilator effect of crocin instead of the COX-1-mediated PGI(2) pathway. Additionally, the anti-contractile effect of crocin was abolished after the blockade of KCa3.1, suggesting that KCa3.1 might be a key regulator, like NO, in the vasodilator effect of crocin. These data indicated that the underlying mechanism of the vasodilator effect of crocin occurs partially through either the NO or the KCa3.1 pathways, but not the PGI pathway, in an endotheliumdependent manner. Furthermore, it is fascinating that the contractive responses of crocinpretreated artery rings to PE appeared desensitized and weakened. These data provide novel insights into the beneficial effects of crocin as a potential therapeutic for its preventive effect in hypertensive disorder.
Next we proved that crocin upregulated the expression of p-eNOS and t-eNOS. Most importantly, we show increased eNOS activity as well as NO production in crocin exposed HUVECs and HUAECs. In fact, previous studies have also confirmed that crocin could promote eNOS activation and NO generation [34] , which our results support. Moreover, these results complement our myograph study findings which showed that crocin relaxed the pre-contracted artery rings through the eNOS-mediated NO pathway. Our previous work showed KCa3.1 played a key role in the vasodilator effect of crocin, suggesting KCa3.1 might be mediated by crocin. However, both western blotting and immunofluorescence staining revealed that KCa3.1 expression was not altered in the presence of crocin. These findings revealed that crocin could possibly activate KCa3.1 in an agonist-like manner, but not cause an increase in overall KCa3.1 expression, in order to regulate the crocin-induced vasodilator effect. To further analyze how KCa3.1 mediates this process, we next investigated the expression of p-eNOS and t-eNOS, as well as NO generation, through the inclusion of the inhibitor TRAM-34 and/or siKCa3.1. Results showed that both TRAM-34 and siKCa3.1 significantly inhibited the upregulation of p-eNOS and t-eNOS, as well as NO generation. Therefore we considered that KCa3.1, at least partially, should be involved in the vasodilator effect of crocin by mediating p-eNOS and t-eNOS expressions in endothelium. We show here first that KCa3.1 might play an important role in the regulation of the eNOS-mediated NO pathway in endothelium.
As shown in previous studies, hyperpolarization could promote membrane potentialdriven Ca 2+ influx and EDHF generation in vascular endothelium [35] . Due to the inducedhyperpolarization of KCa3.1 in endothelium, we hypothesized that crocin may activate the mobilization of intracellular Ca 2+ in endothelium via the activation of KCa3.1. In fact, our subsequent work from Fig. 4A completely supports this hypothesis. Other authors have established that the cardiovascular protective effects of crocin were associated with inhibition of Ca 2+ elevation in vascular smooth muscle cells [5] or cardiomyocytes [36] . These findings were ascribed to the inhibition of the L-type Ca 2+ channel by crocin. However, the underlying molecular mechanisms by which crocin mediates intracellular Ca 2+ in endothelium remained to be explored. We found that the blockade of KCa3.1 significantly suppressed the elevation of Ca 2+ induced by crocin (Fig. 4C ). This evidence indicates that crocin may stimulate the activation of KCa3.1 and subsequently the hyperpolarization of the endothelium. This hyperpolarization then induces membrane potential-driven Ca 2+ influx via nonselective cation channels (NSCC), not L-type Ca 2+ channels. It has been previously reported and established that COX has two isoforms: COX-1 and COX-2. COX-1, as the predominate isoform which produces PGI(2) to relax blood vessels, is constitutively expressed in healthy endothelial cells. Conversely, COX-2, an inducible isoform mainly correlated with inflammation, is induced by cytokines and pathogen-associated molecular patterns in diseased endothelial cells [37] . In our work, we found that crocin could not affect COX-1 expression, which significantly complements our previous findings that the COX-1-mediated PGI(2) system did not play a major role in the vasodilator effect of crocin in artery. However, the expression of COX-2 repeatedly increased in our work, suggesting that this increase in COX-2 may serve as a protective response to the activation of endothelial cells induced by crocin. Additionally, the COX-1-mediated PGI(2) pathway needs activation of phospholipase A 2 (PLA 2 ), which requires a high Ca 2+ burst resulting from the emptying of intracellular stores. However, eNOS activation has a lower requirement for Ca 2+ than PLA 2 in comparison [37] . Here, we propose that crocin-stimulated KCa3.1 activation should induce a low intracellular Ca 2+ level, and that this concentration of Ca
2+
, while enough for the activation of eNOS, is deficient for PLA 2 . Conceivably, this may explain the reason why crocin was unable to induce ring relaxation through the COX-1-mediated PGI(2) pathway.
In addition to vasodilators and vasoconstrictors released by endothelium, the expressions of other endothelial cell markers including CD31, TM, ICAM-1 and VCAM-1 are altered in response to endothelial dysfunction. Several studies confirmed that CD31 expression decreased due to endothelial dysfunction in diabetes [38, 39] . Likewise, endothelial damage or dysfunction always causes the proteolytic cleavage of TM, leading to the lower expression of TM on endothelium [40] . This damaged induced cleavage of the endothelial cell surface protein, TM, serves as a central biomarker for cardiovascular disease. Thus, the alteration of CD31 or TM expression, to some extent, reflects a change in endothelial function. In this study, we have provided evidence that crocin significantly upregulated the expression of CD31 and TM, indicating that crocin could improve endothelial function and exert beneficial effects on vascular pathologies. The adhesion molecules ICAM-1 and VCAM-1, expressed on the endothelial cell surface, play pivotal roles in the recruitment and transendothelial migration of leucocytes and subsequent inflammation [40] [41] [42] . ICAM-1 and VCAM-1 expression tended to be upregulated during physiological and pathological endothelial activation [43] [44] [45] . Previous studies show that crocin possesses an anti-inflammatory effect via the reduction of some proinflammatory cytokines including tumor necrosis factor-α (TNF-α) and interleukin (IL)-6 [46] [47] [48] . However the effects of crocin on ICAM-1 and VCAM-1 remains unclear. Our data suggested that crocin could stimulate the expression of VCAM-1 at the protein level and showed a tendency to increase ICAM-1, but with no significant statistical difference. We speculate that VCAM-1 upregulation could represent the endothelial activation induced by crocin. The treatment of cells with crocin facilitates the improvement of endothelial function, which is connected with endothelial activation. Moreover, cell viability and migration also reflect the activation of endothelium. In our research, we observed that crocin could significantly stimulate endothelial cell viability and migration. Other authors have described that crocin could inhibit endothelial cell apoptosis and protect the endothelium against damage [11, 26] , which partially aligns with our studies. However, many studies demonstrated that crocin significantly suppressed cell proliferation in various cancer cells, including breast cancer cells and colorectal cancer cells [49] [50] [51] . These data contrast with our present results in endothelial cells and the discrepancy may be due to tissue differences in the effects of crocin.
Among the family of well-known serine/threonine-specific protein kinases, mitogenactivated protein kinases (MAPK) and Akt are two central components of activated signaling pathways in endothelial cells. These signaling pathways regulate diverse cellular functions including cell growth, proliferation, survival, and migration in endothelial and other cell types [27, [52] [53] [54] . Previous studies have demonstrated that the activation of the MAPK/ ERK and PI3K/Akt signaling pathways were involved in HUVEC proliferation and migration [27, 52, 53] . In our present work, we postulated that both the MAPK/ERK and PI3K/Akt signaling pathways might be involved in the activity of crocin on endothelium. Among these activities we evaluated the influence of crocin on the expression of p-eNOS, t-eNOS, CD31, TM, VCAM-1, intracellular Ca 2+ concentration, NO generation as well as cellular proliferation and migration. Notably, crocin could not affect the KCa3.1 expression, but the inhibition of MAPK/ERK and PI3K/Akt pathways could downregulate KCa3.1 expression. In fact, this finding agrees with our previous work which reported that the MEK inhibitor PD98059 Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry suppressed KCa3.1 expression in HUVECs [27] . These data indicate that both the MAPK/ ERK and PI3K/Akt signaling pathways could be involved in the activation of KCa3.1 in the endothelium. This is also consistent with the report that the MEK/ERK pathway regulates the function of endothelial KCa3.1 [55] . Based on these data, we propose that crocin exerted these effects on the vascular endothelial cells through activation of the MAPK/ERK and PI3K/ Akt signaling pathways. Our data strongly supports that both the MAPK/ERK and PI3K/Akt signaling pathways could be involved in the activation of KCa3.1 in endothelium.
Conclusion
In summary, coupled with its known antioxidant effects on endothelium, our study demonstrates that crocin exerts protective effects on vascular endothelial cells through improvement of endothelial function via the elevation of eNOS-mediated NO, CD31 and TM. Furthermore, the activations of both the MAPK/ERK and PI3K/Akt signaling pathways play crucial roles in this process. Our study for the first time provides new insight into the protective effects of crocin where KCa3.1 might function on endothelial cells as a pivotal modulator. As presented in Fig. 8 , crocin induces some increase in intracellular Ca 2+ concentration through stimulating the MAPK/ERK and/or PI3K/Akt signaling pathways. This increased intracellular Ca 2+ activates KCa3.1 and leads to the subsequent hyperpolarization of endothelium. Endothelial hyperpolarization further induces membrane potential-driven Ca 2+ influx and the subsequent increase of intracellular Ca 2+ levels, resulting indirectly in eNOS activation and NO synthesis. An alternative mechanism could be that the activation of KCa3.1 by crocin causes the hyperpolarization of endothelium. This could then be propagated to the smooth muscle cells via gap-junctions, leading directly to inhibition of Ca 2+ influx and subsequent EDHF-type dilations in vessels [18, 25, 56] , as based on previous research. Future research could explore whether it is through another mechanism that crocin possesses the vasodilator effect via KCa3.1-mediated hyperpolarization in endothelial and smooth muscle cells. 
